|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
|
31165342 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our patient is the youngest patient who received vemurafenib for BRAF V600 mutation-positive metastatic melanoma in the literature.
|
30376464 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous toxicities associated with BRAF inhibitor treatment in patients with metastatic melanoma have been well described.
|
30601209 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combination therapy with BRAF and MEK inhibitors dramatically improves response rates, progression-free survival and overall survival in patients with BRAF-mutant metastatic melanoma compared to historical treatments such as chemotherapy.
|
30977681 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Materials & methods:</b> Physicians-identified BRAF mutant MM patients initiating 1L TT or IO therapies and extracted treatment, disease and clinical outcomes including disease response which were compared between TT and IO and individual regimens.
|
30799646 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CTC-derived biomarkers and clinical variables analyzed using classification and regression tree analysis revealed that a combination of lactate dehydrogenase, CTC-mRNA biomarkers, and tumor BRAF-mutation status was indicative of clinical outcomes for patients with stage IV melanoma (n = 52).
|
31672856 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two patients presenting a BRAF-mutated metastatic melanoma were treated with cobimetinib and vemurafenib.
|
31260421 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
|
30652516 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
|
30690294 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected.
|
31817189 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, recent breakthroughs have brought new hopes for patients and providers.While targeted therapy with BRAF and MEK inhibitors represents an important cornerstone in the treatment of metastatic melanoma, this chapter carefully reviews the past and current therapy options available, with a significant focus on immunotherapy-based approaches.
|
30539505 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK inhibitor therapy for <i>BRAF</i><sup>V600</sup>-mutated metastatic melanoma.
|
30824584 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.
|
31213499 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We reviewed the literature to assess the efficacy and risk of constitutional, cardiac, gastrointestinal, and dermatological toxicities of combined BRAF plus MEK inhibitors versus BRAF inhibitors alone in patients with metastatic melanoma with BRAF mutations.
|
31817473 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current case series study describes the utility of neutrophil count (NC), neutrophil ratio (NR) and C-reactive protein (CRP) in 11 patients with metastatic melanoma and BRAF V600 mutations who experienced pyrexia during combi-DT in our department.
|
31180164 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of our retrospective analysis was to determine the efficacy and safety of vemurafenib therapy for BRAF mutated metastatic melanoma and subsequently to prove the clinical benefit for the studied 43 patients, based on real-life data.
|
28963614 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF and MEK inhibitors have been shown to improve overall and progression-free survival among patients with metastatic melanoma.
|
31050693 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a patient with BRAF-V600E-positive metastatic melanoma who was sequentially treated with BRAF/MEK inhibitors (dabrafenib/trametinib) and checkpoint inhibitor immunotherapy (nivolumab, followed by pembrolizumab).
|
31082388 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
|
31527213 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This single-arm, phase 2 study enrolled patients with stage IV melanoma who were refractory to checkpoint inhibition and to B-raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibition (in the presence of a BRAF valine mutation at codon 600).
|
30690710 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have demonstrated that although BRAF mutation is a negative prognostic factor in stage IV melanoma, the use of two different systemic treatment modalities allows achievement of comparable survival in BRAF mutated and BRAF wild-type patients.
|
31754963 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a case of BRAF-mutated MM who presented with DMC.
|
31473636 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
|
31095039 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitors (BRAFi), in combination with MEK inhibitors, also resulted in improved overall survival compared with single-agent BRAFi in patients with <i>BRAFV600</i>-mutated metastatic melanoma.
|
31205512 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because of the conflicting conclusions on BRAF mutations in the natural course of non-metastatic melanoma their prognostic significance is still controversial.
|
31058533 |
2019 |